Kevin Jeffery Barnham
#158,307
Most Influential Person Now
Kevin Jeffery Barnham's AcademicInfluence.com Rankings
Kevin Jeffery Barnhammathematics Degrees
Mathematics
#7269
World Rank
#9911
Historical Rank
Probability Theory
#117
World Rank
#143
Historical Rank
Download Badge
Mathematics
Why Is Kevin Jeffery Barnham Influential?
(Suggest an Edit or Addition)Kevin Jeffery Barnham's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Neurodegenerative diseases and oxidative stress (2004) (3250)
- Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice (2001) (1349)
- Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ (2008) (614)
- Metals in Alzheimer's and Parkinson's diseases. (2008) (606)
- Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease (2010) (585)
- Alzheimer's Disease Amyloid-β Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits* (2001) (578)
- The redox chemistry of the Alzheimer's disease amyloid β peptide (2007) (528)
- Biological metals and metal-targeting compounds in major neurodegenerative diseases. (2014) (333)
- Copper-Dependent Inhibition of Human Cytochrome c Oxidase by a Dimeric Conformer of Amyloid-β1-42 (2005) (318)
- Cisplatin Binding Sites on Human Albumin* (1998) (302)
- 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. (2011) (280)
- Degradation of the Alzheimer Disease Amyloid β-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity* (2006) (271)
- Structure of the Alzheimer's Disease Amyloid Precursor Protein Copper Binding Domain (2003) (259)
- Dopamine promotes α‐synuclein aggregation into SDS‐resistant soluble oligomers via a distinct folding pathway (2005) (255)
- Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. (2001) (246)
- Inhibition of γ‐secretase causes increased secretion of amyloid precursor protein C‐terminal fragments in association with exosomes (2008) (244)
- Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease β‐amyloid (2004) (238)
- Increasing Cu bioavailability inhibits Aβ oligomers and tau phosphorylation (2009) (226)
- Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics (2006) (221)
- SOD1 (Copper/Zinc Superoxide Dismutase) Deficiency Drives Amyloid β Protein Oligomerization and Memory Loss in Mouse Model of Alzheimer Disease* (2011) (216)
- Amyloid-β Peptide (Aβ) Neurotoxicity Is Modulated by the Rate of Peptide Aggregation: Aβ Dimers and Trimers Correlate with Neurotoxicity (2008) (208)
- Pleomorphic copper coordination by Alzheimer's disease amyloid-beta peptide. (2009) (200)
- Interaction of the Molecular Chaperone αB-Crystallin with α-Synuclein: Effects on Amyloid Fibril Formation and Chaperone Activity (2004) (199)
- Metal Ions, pH, and Cholesterol Regulate the Interactions of Alzheimer's Disease Amyloid-β Peptide with Membrane Lipid* (2003) (195)
- Neurotoxic, Redox-competent Alzheimer's β-Amyloid Is Released from Lipid Membrane by Methionine Oxidation* (2003) (190)
- The redox chemistry of the Alzheimer's disease amyloid beta peptide. (2007) (185)
- Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide. (2005) (175)
- Characterization of unique amphipathic antimicrobial peptides from venom of the scorpion Pandinus imperator. (2001) (175)
- Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease (2012) (175)
- The Alzheimer’s therapeutic PBT2 promotes amyloid‐β degradation and GSK3 phosphorylation via a metal chaperone activity (2011) (168)
- Copper-mediated Amyloid-β Toxicity Is Associated with an Intermolecular Histidine Bridge* (2006) (168)
- Selective Intracellular Release of Copper and Zinc Ions from Bis(thiosemicarbazonato) Complexes Reduces Levels of Alzheimer Disease Amyloid-β Peptide* (2008) (163)
- A rigorous method to enrich for exosomes from brain tissue (2017) (160)
- Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. (2007) (160)
- In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies (2007) (159)
- Platinum-based inhibitors of amyloid-β as therapeutic agents for Alzheimer's disease (2008) (157)
- Ring-Opened Adducts of the Anticancer Drug Carboplatin with Sulfur Amino Acids. (1996) (155)
- Alanine-2 carbonyl is an oxygen ligand in Cu2+ coordination of Alzheimer's disease amyloid-beta peptide--relevance to N-terminally truncated forms. (2009) (144)
- Amyloid-β Peptide Disruption of Lipid Membranes and the Effect of Metal Ions (2006) (143)
- The heterogeneous nature of Cu2+ interactions with Alzheimer's amyloid-β peptide. (2011) (139)
- The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease (2012) (136)
- Alzheimer's disease & metals: therapeutic opportunities (2011) (123)
- Alzheimer disease β-amyloid activity mimics cholesterol oxidase (2005) (122)
- Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease (2014) (121)
- Oral Treatment with CuII(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (2014) (119)
- Diacetylbis(N(4)-methylthiosemicarbazonato) Copper(II) (CuII(atsm)) Protects against Peroxynitrite-induced Nitrosative Damage and Prolongs Survival in Amyotrophic Lateral Sclerosis Mouse Model* (2011) (118)
- Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation. (2009) (110)
- Methylation of the Imidazole Side Chains of the Alzheimer Disease Amyloid-β Peptide Results in Abolition of Superoxide Dismutase-like Structures and Inhibition of Neurotoxicity* (2005) (106)
- The Caenorhabditis elegans Aβ1–42 Model of Alzheimer Disease Predominantly Expresses Aβ3–42* (2009) (106)
- Intermolecular displacement of S-bound L-methionine on platinum(II) by guanosine 5′-monophosphate: implications for the mechanism of action of anticancer drugs (1994) (105)
- Therapeutic redistribution of metal ions to treat Alzheimer's disease. (2012) (105)
- Delineating common molecular mechanisms in Alzheimer's and prion diseases. (2006) (105)
- Enhanced Toxicity and Cellular Binding of a Modified Amyloid β Peptide with a Methionine to Valine Substitution* (2004) (99)
- Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity (2008) (98)
- Structural studies of the Alzheimer's amyloid precursor protein copper-binding domain reveal how it binds copper ions. (2007) (97)
- Cu2+ binding modes of recombinant alpha-synuclein--insights from EPR spectroscopy. (2008) (94)
- Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. (2009) (93)
- The structure of the amyloid-beta peptide high-affinity copper II binding site in Alzheimer disease. (2008) (93)
- Modulation of α-Synuclein Aggregation by Dopamine: A Review (2009) (93)
- Risk prediction of late-onset Alzheimer’s disease implies an oligogenic architecture (2020) (86)
- Methionine regulates copper/hydrogen peroxide oxidation products of Aβ (2005) (85)
- Stabilization of Neurotoxic Soluble β-Sheet-Rich Conformations of the Alzheimer's Disease Amyloid-β Peptide (2008) (78)
- Diagnostic imaging agents for Alzheimer's disease: copper radiopharmaceuticals that target Aβ plaques. (2013) (78)
- A Functional Role for Aβ in Metal Homeostasis? N-Truncation and High-Affinity Copper Binding. (2015) (78)
- Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease. (2000) (77)
- Blood-Borne Amyloid-β Dimer Correlates with Clinical Markers of Alzheimer's Disease (2010) (76)
- Restored degradation of the Alzheimer’s amyloid‐β peptide by targeting amyloid formation (2009) (76)
- Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis (2013) (75)
- The structure of dopamine induced α-synuclein oligomers (2010) (75)
- Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples (2013) (74)
- Radioiodinated clioquinol as a biomarker for β‐amyloid: Zn2+ complexes in Alzheimer's disease (2006) (74)
- Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity. (2004) (69)
- Copper binding to the Alzheimer’s disease amyloid precursor protein (2007) (68)
- Formation of a high affinity lipid-binding intermediate during the early aggregation phase of alpha-synuclein. (2008) (67)
- Outer-Sphere Macrochelation in [Pd(en)(5'-GMP-N7)2].cntdot.9H2O and [Pt(en)(5'-GMP-N7)2].cntdot.9H2O: X-ray Crystallography and NMR Spectroscopy in Solution (1995) (66)
- The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease (2017) (64)
- Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons* (2015) (64)
- Differential modulation of Alzheimer's disease amyloid beta-peptide accumulation by diverse classes of metal ligands. (2007) (61)
- CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease (2020) (61)
- Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease. (2010) (60)
- Characterization and Identification of Dityrosine Cross-Linked Peptides Using Tandem Mass Spectrometry. (2017) (59)
- Identification of platination sites on human serum transferrin using 13C and 15N NMR spectroscopy (1999) (58)
- Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target? (2014) (58)
- Metal catalyzed oxidation of tyrosine residues by different oxidation systems of copper/hydrogen peroxide. (2004) (58)
- L-Methionine increases the rate of reaction of 5′-guanosine monophosphate with the anticancer drug cisplatin: mixed-ligand adducts and reversible methionine binding (1995) (58)
- A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-beta plaques. (2010) (56)
- Aspects of the solution chemistry of trans-diammineplatinum(II) complexes (1992) (55)
- A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study (2017) (54)
- Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. (2005) (53)
- Development of a platinum complex as an anti-amyloid agent for the therapy of Alzheimer's disease. (2013) (52)
- Pharmacotherapeutic targets in Alzheimer's disease (2008) (51)
- Stabilization of Nontoxic Aβ-Oligomers: Insights into the Mechanism of Action of Hydroxyquinolines in Alzheimer's Disease (2015) (51)
- Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. (2008) (51)
- Mixed ligand Cu2+ complexes of a model therapeutic with Alzheimer's amyloid-β peptide and monoamine neurotransmitters. (2013) (50)
- Ferric Ions Are Essential for the Biological Activity of the Hormone Glycine-extended Gastrin* (2002) (50)
- Iron inhibits neurotoxicity induced by trace copper and biological reductants (2004) (50)
- Stereospecific interactions are necessary for Alzheimer disease amyloid-β toxicity (2011) (50)
- Solution structure of a polypeptide from the N terminus of the HIV protein Nef. (1997) (50)
- Kinetic Analysis of the Stepwise Platination of Single‐ and Double‐Stranded GG Oligonucleotides with Cisplatin and cis‐[PtCl(H2O)(NH3)2]+ (1996) (49)
- Dimeric structures of alpha-synuclein bind preferentially to lipid membranes. (2008) (49)
- Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. (2008) (49)
- 18 F-THK 523 : a novel in vivo tau imaging ligand for Alzheimer ’ s disease (2011) (46)
- Synthesis of 2-pyridyl-benzimidazole iridium(III), ruthenium(II), and platinum(II) complexes. study of the activity as inhibitors of amyloid-β aggregation and neurotoxicity evaluation. (2015) (46)
- Alzheimer's Aβ Peptides with Disease-Associated N-Terminal Modifications: Influence of Isomerisation, Truncation and Mutation on Cu2+ Coordination (2010) (45)
- The Caenorhabditis elegans A beta(1-42) Model of Alzheimer Disease Predominantly Expresses A beta(3-42) (2009) (45)
- Increasing Cu bioavailability inhibits A beta oligomers and tau phosphorylation (2009) (44)
- Membrane interactions and the effect of metal ions of the amyloidogenic fragment Aβ(25–35) in comparison to Aβ(1–42) (2007) (44)
- Parkinsonism as a Third Wave of the COVID-19 Pandemic? (2020) (43)
- Increased ATP-binding cassette transporter A1 expression in Alzheimer's disease hippocampal neurons. (2010) (42)
- Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer’s disease (2020) (41)
- Copper‐dependent inhibition of cytochrome c oxidase by Aβ1−42 requires reduced methionine at residue 35 of the Aβ peptide (2006) (41)
- Synthetic dityrosine-linked β-amyloid dimers form stable, soluble, neurotoxic oligomers (2013) (41)
- Conservation of a Glycine-rich Region in the Prion Protein Is Required for Uptake of Prion Infectivity* (2010) (40)
- Small RNA fingerprinting of Alzheimer’s disease frontal cortex extracellular vesicles and their comparison with peripheral extracellular vesicles (2020) (39)
- Platination Pathways for Reactions of Cisplatin with GG Single-Stranded and Double-Stranded Decanucleotides† (1995) (39)
- Dominant roles of the polybasic proline motif and copper in the PrP23-89-mediated stress protection response (2009) (39)
- PKA VALUES OF AQUA LIGANDS OF PLATINUM(II) ANTICANCER COMPLEXES : 1H, 15N AND 195PT NMR STUDIES OF CIS- AND TRANS- PTCL2(NH3)(CYCLOHEXYLAMINE) (1998) (38)
- Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. (2012) (38)
- [Pt(CBDCA-O)(NH3)2(L-Methionine-S)]: Ring-Opened Adduct of the Anticancer Drug Carboplatin ("Paraplatin"). Detection of a Similar Complex in Urine by NMR Spectroscopy (1994) (38)
- Copper and zinc bis(thiosemicarbazonato) complexes with a fluorescent tag: synthesis, radiolabelling with copper-64, cell uptake and fluorescence studies (2010) (37)
- Solid-phase synthesis of homodimeric peptides: preparation of covalently-linked dimers of amyloid beta peptide. (2009) (37)
- Oral Treatment with Cu [ superscript II ] ( atsm ) Increases Mutant SOD 1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (2014) (37)
- Metal homeostasis in Alzheimer’s disease (2006) (37)
- Model studies of cholesterol and ascorbate oxidation by copper complexes: relevance to Alzheimer's disease beta-amyloid metallochemistry. (2005) (36)
- Characterization of brain‐derived extracellular vesicle lipids in Alzheimer's disease (2020) (36)
- Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. (2010) (35)
- Cholesterol and Clioquinol modulation of A beta(1-42) interaction with phospholipid bilayers and metals. (2007) (35)
- Therapeutic treatments for Alzheimer's disease based on metal bioavailability. (2006) (34)
- Sustained activation of glial cell epidermal growth factor receptor by bis(thiosemicarbazonato) metal complexes is associated with inhibition of protein tyrosine phosphatase activity. (2009) (34)
- Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. (2006) (33)
- Structure of neurotoxin B-IV from the marine worm Cerebratulus lacteus: a helical hairpin cross-linked by disulphide bonding. (1997) (32)
- Structural insights into the interaction of platinum-based inhibitors with the Alzheimer's disease amyloid-β peptide. (2013) (32)
- Stabilization of monofunctional platinum–nucleotide adducts: reactions of N-acetyl-L-methionine complexes with guanosine 5′-monophosphate and guanylyl(3′–5′)guanosine (1996) (32)
- Structure of a Novel P-superfamily Spasmodic Conotoxin Reveals an Inhibitory Cystine Knot Motif* 210 (2002) (32)
- Anionic Phospholipid Interactions of the Prion Protein N Terminus Are Minimally Perturbing and Not Driven Solely by the Octapeptide Repeat Domain* (2010) (32)
- Copper Modulation of Ion Channels of PrP[106–126] Mutant Prion Peptide Fragments (2003) (31)
- Copper and Zinc Mediated Oligomerisation of Aβ Peptides (2006) (31)
- Role of the 6‐20 disulfide bridge in the structure and activity of epidermal growth factor (1998) (31)
- Histidine 14 modulates membrane binding and neurotoxicity of the Alzheimer's disease amyloid-beta peptide. (2010) (28)
- Alpha-synuclein oligomers and fibrils originate in two distinct conformer pools: a small angle X-ray scattering and ensemble optimisation modelling study. (2015) (27)
- The Amyloid Precursor Protein Copper Binding Domain Histidine Residues 149 and 151 Mediate APP Stability and Metabolism* (2012) (26)
- Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide. (2008) (25)
- Amyloid-β: the seeds of darkness. (2011) (24)
- Copper-dependent inhibition of cytochrome c oxidase by Abeta(1-42) requires reduced methionine at residue 35 of the Abeta peptide. (2006) (23)
- Metals, membranes, and amyloid-β oligomers: key pieces in the Alzheimer's disease puzzle? (2012) (23)
- Activation of epidermal growth factor receptor by metal-ligand complexes decreases levels of extracellular amyloid beta peptide. (2008) (23)
- Near-infrared fluorescence imaging of apoptotic neuronal cell death in a live animal model of prion disease. (2010) (23)
- Characterizing bathocuproine self‐association and subsequent binding to Alzheimer's disease amyloid β‐peptide by NMR (2004) (23)
- Antiviral Activity and Structural Characteristics of the Nonglycosylated Central Subdomain of Human Respiratory Syncytial Virus Attachment (G) Glycoprotein* (2001) (23)
- Dimerisation of N-acetyl-l-tyrosine ethyl ester and Aβ peptides via formation of dityrosine (2006) (22)
- Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. (2013) (22)
- A Novel Effect of Bismuth Ions (2004) (22)
- Pathogenic Mutations within the Hydrophobic Domain of the Prion Protein Lead to the Formation of Protease-Sensitive Prion Species with Increased Lethality (2013) (21)
- Cell cycle arrest in cultured neuroblastoma cells exposed to a bis(thiosemicarbazonato) metal complex (2011) (21)
- Small angle X-ray scattering analysis of Cu(2+)-induced oligomers of the Alzheimer's amyloid β peptide. (2015) (19)
- Quantification of N-terminal amyloid-β isoforms reveals isomers are the most abundant form of the amyloid-β peptide in sporadic Alzheimer’s disease (2021) (19)
- Metal-catalyzed oxidative damage and oligomerization of the amyloid-β peptide of Alzheimer’s disease (2004) (19)
- Effect of Structural Modifications to Glyoxal-bis(thiosemicarbazonato)copper(II) Complexes on Cellular Copper Uptake, Copper-Mediated ATP7A Trafficking, and P-Glycoprotein Mediated Efflux. (2018) (18)
- Neurological Dysfunction in Early Maturity of a Model for Niemann–Pick C1 Carrier Status (2016) (17)
- Gene dysregulation is restored in the Parkinson’s disease MPTP neurotoxic mice model upon treatment of the therapeutic drug CuII(atsm) (2016) (17)
- Quantification of copper binding to amyloid precursor protein domain 2 and its Caenorhabditis elegans ortholog. Implications for biological function. (2014) (17)
- [Pd(CBDCA-O,O′)(NH3)2]: the PdII analogue of a platinum anticancer drug (CBDCA = cyclobutane-1,1-dicarboxylate) (1994) (17)
- Structural transitions of a GG-platinated DNA duplex induced by pH, temperature and box A of high-mobility-group protein 1. (1997) (17)
- Modulating metals as a therapeutic strategy for Alzheimer's disease. (2012) (17)
- Optical Imaging Detects Apoptosis in the Brain and Peripheral Organs of Prion-Infected Mice (2011) (17)
- Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease. (2011) (16)
- Rhenium and technetium complexes that bind to amyloid-β plaques. (2015) (16)
- α-Helix unfolding in simple shear flow (2011) (16)
- Peripheral α-defensins 1 and 2 are elevated in Alzheimer's disease. (2015) (16)
- Modification of Biodistribution and Brain Uptake of Copper Bis(thiosemicarbazonato) Complexes by the Incorporation of Amine and Polyamine Functional Groups. (2019) (16)
- Neurotoxic species in prion disease: a role for PrP isoforms? (2007) (16)
- Stereospecific interactions are necessary for Alzheimer's disease amyloid-beta toxicity (2009) (15)
- Cu2+-induced modification of the kinetics of Aβ(1-42) channels (2003) (15)
- Neurotoxicity in Alzheimer’s disease: is covalently crosslinked Aβ responsible? (2008) (14)
- PBT2 inhibits glutamate-induced excitotoxicity in neurons through metal-mediated preconditioning (2015) (14)
- [1H,15N] N.M.R. Kinetic Studies of Reactions of cis- and trans-[PtCl2(15NH3)(c-C6H1115NH2)] with Guanosine 5'-Monophosphate (1999) (14)
- Magnetic Resonance Studies of β-Amyloid Peptides (2003) (13)
- Alzheimer's Disease and Metals: A Review of the Involvement of Cellular Membrane Receptors in Metallosignalling (2011) (13)
- Helical structure and self-association in a 13 residue neuropeptide Y Y2 receptor agonist: relationship to biological activity. (1999) (12)
- Reactions of Nitroplatinum Complexes. 2. Reactions of K2[Pt(NO2)4] and Related Complexes with Aqueous Acids (CH3CO2H, HClO4, CF3SO3H, HNO3, and H2SO4): Pathways to Platinum(III) Complexes with Acetate Bridges. Crystal Structure of K2[{Pt(NO2)2(.mu.-CH3CO2)}2].cntdot.H2O (1995) (12)
- Copper catalysed oxidation of amino acids and Alzheimer's disease (2003) (12)
- Synthesis of Oxorhenium(V) and Oxotechnetium(V) Complexes That Bind to Amyloid-β Plaques. (2016) (12)
- Targeting metals rescues the phenotype in an animal model of tauopathy. (2018) (12)
- The Val-210-Ile pathogenic Creutzfeldt-Jakob disease mutation increases both the helical and aggregation propensities of a sequence corresponding to helix-3 of PrP(C). (2001) (12)
- The N-Terminal Residues 43 to 60 Form the Interface for Dopamine Mediated α-Synuclein Dimerisation (2015) (11)
- C-terminal peptides modelling constitutive PrPC processing demonstrate ameliorated toxicity predisposition consequent to α-cleavage. (2014) (11)
- Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies. (2018) (11)
- Metal-Protein Attenuating Compounds (MPACs) for the Treatment of Alzheimers Disease (2004) (11)
- Biological activity and ferric ion binding of fragments of glycine-extended gastrin. (2004) (11)
- Structure and Activity of D-Pro14 Melittin (2002) (11)
- Neurotoxicity in Alzheimer's disease: is covalently crosslinked A beta responsible? (2008) (11)
- Membrane interactions and the effect of metal ions of the amyloidogenic fragment Abeta(25-35) in comparison to Abeta(1-42). (2007) (10)
- Crystallization and preliminary X-ray diffraction analysis of the Fab fragment of WO2, an antibody specific for the Abeta peptides associated with Alzheimer's disease. (2008) (10)
- Ablation of tau causes an olfactory deficit in a murine model of Parkinson’s disease (2018) (10)
- Guanidine hydrochloride denaturation of dopamine‐induced α‐synuclein oligomers: A small‐angle X‐ray scattering study (2014) (10)
- Copper Coordination by Familial Mutants of Parkinson’s Disease-Associated α-Synuclein (2009) (10)
- Reactions of nitroplatinum complexes. 1. 15N and 195Pt NMR spectra of platinum(II) nitrite complexes (1991) (9)
- The Aβcentric Pathway of Alzheimer’s Disease (2007) (9)
- Is Covalently Crosslinked Aβ Responsible for Synaptotoxicity in Alzheimers Disease (2008) (9)
- Microwave Synthesis of Prion Protein Fragments up to 111 Amino Acids in Length Generates Biologically Active Peptides (2012) (9)
- Crystallization and preliminary crystallographic studies of the copper-binding domain of the amyloid precursor protein of Alzheimer's disease. (2005) (9)
- Increased Expression of the Lysosomal Cholesterol Transporter NPC1 in Alzheimer's Disease (2010) (8)
- X-RAY CRYSTAL STRUCTURE DETERMINATION AND SPECTROSCOPIC CHARACTERIZATION OF TRANS-DIAMMINEDIHYDROXOPLATINUM(II) DIHYDRATE (1996) (8)
- Methionine oxidation: Implications for the mechanism of toxicity of the β-amyloid peptide from Alzheimer's disease (2003) (8)
- Molecular determinants of Alzheimer’s disease Aβ peptide neurotoxicity (2007) (8)
- P1-422: Abeta neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity (2008) (7)
- Electron paramagnetic resonance characterization of the copper-resistance protein PcoC from Escherichia coli (2008) (7)
- Biophysical investigations of the prion protein using electron paramagnetic resonance. (2008) (7)
- Reduced striatal vesicular monoamine transporter 2 in REM sleep behavior disorder: imaging prodromal parkinsonism (2020) (7)
- A commonly used Drosophila model of Alzheimer's disease generates an aberrant species of amyloid‐β with an additional N‐terminal glutamine residue (2014) (6)
- The social defeat/overcrowding murine psychosocial stress model results in a pharmacologically reversible body weight gain but not depression - related behaviours (2018) (6)
- Is covalently crosslinked Abeta responsible for synaptotoxicity in Alzheimer's disease? (2008) (6)
- Cu2+ Coordination of Covalently Cross-linked β-Amyloid Dimers (2013) (5)
- Generation of soluble oligomeric β-amyloid species via copper catalyzed oxidation with implications for Alzheimer’s disease: A DFT study (2010) (5)
- Methionine oxidation: Implications for the mechanism of toxicity of the β-amyloid peptide from Alzheimer's disease (2003) (5)
- S-Adenosylmethionine Rescues Cognitive Deficits in the rTg4510 Animal Model by Stabilizing Protein Phosphatase 2A and Reducing Phosphorylated Tau. (2020) (5)
- Cu2+-induced modification of the kinetics of A beta(1-42) channels. (2003) (4)
- ATH434 Reverses Colorectal Dysfunction in the A53T Mouse Model of Parkinson’s Disease (2021) (4)
- Free Radicals, Metal Ions, and Aβ Aggregation and Neurotoxicity (2007) (4)
- Anti-Aβ antibody target engagement: a response to Siemers et al. (2014) (4)
- Amyloid-beta: The seeds of darkness (2011) (4)
- A Copper Radiopharmaceutical for Diagnostic Imaging of Alzheimer′s Disease: A Bis(thiosemicarbazonato)copper(II) Complex That Binds to Amyloid‐β Plaques. (2010) (4)
- NMR Spectroscopy of Platinum Drugs: From DNA to Body Fluids (1996) (4)
- O3-04-06 Structural and functional analysis of the Alzheimer's disease amyloid precursor protein copper binding domain (2004) (3)
- Aβ Metallobiology and the Development of Novel Metal-Protein Attenuating Compounds (MPACs) for Alzheimers Disease (2003) (3)
- The role of autophagy in potentially therapeutic copper complexes (2009) (3)
- Aspects of the Solution Chemistry of trans-Diammineplatinum(II) Complexes. (1992) (3)
- The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy (2021) (3)
- P2-293: Platinum-based inhibitors of amyloid-β as therapeutic agents for Alzheimer's disease (2008) (3)
- Variability in blood-based beta-amyloid assays: The need for consensus on preanalytical processing (2012) (3)
- 1 CUII ( ATSM ) PROTECTS AGAINST PEROXYNITRITE-INDUCED NITROSATIVE DAMAGE AND PROLONGS SURVIVAL IN AN AMYOTROPHIC LATERAL SCLEROSIS MOUSE MODEL (2011) (2)
- Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegansfor drug screening for Alzheimer’s disease (2012) (2)
- Alzheimer’s Ab Peptides with Disease-Associated N- Terminal Modifications: Influence of Isomerisation, Truncation and Mutation on Cu Coordination (2010) (2)
- Copper catalysed oxidation of amino acids and Alzheimer's disease (2003) (2)
- Magnetic Resonance Studies of β‐Amyloid Peptides. (2003) (2)
- High order W02-reactive stable oligomers of amyloid-β are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid-β monomer. (2015) (2)
- Development of a neuroprotective antioxidant by a mix-and-match strategy - (2013) (2)
- β-amyloid in biological samples: not all Aβ detection methods are created equal (2014) (2)
- Analysis of Abeta interactions using ProteinChip technology. (2008) (2)
- Ablation of tau causes an olfactory deficit in a murine model of Parkinson’s disease (2018) (1)
- P4-435 PBT2, a novel MPAC for the treatment of Alzheimer’s disease (2006) (1)
- II inhibits ferroptosis: implications for treatment of neurodegenerative disease (2019) (1)
- Novel Molecular Mechanisms for the Neurotrophic and Neuroprotective Effects of Pbt2 in Alzheimer's Disease and Huntington's Disease (2010) (1)
- Metal-Catalyzed Oxidative Damage and Oligomerization of the Amyloid-β Peptide of Alzheimer′s Disease (2004) (1)
- Metal chaperones: A holistic approach to the treatment of Alzheimer's disease (2011) (1)
- The Alzheimer's therapeutic PBT2 achieves cognitive benefit by combining neuroprotection with neurorestoration: studies in animal models of Alzheimer's disease and Huntington's disease (2011) (1)
- A novel mechanism for acupuncture-induced analgesia: involvement of orexins and endocannabinoids (2014) (1)
- Comprar Protein Folding, Misfolding, and Disease | Hill, A.F. | 9781603272216 | Springer (2011) (1)
- P4-241 The mechanism by which Aβ produces hydrogen peroxide and its role in neurotoxicity (2004) (1)
- Pre-targeting amyloid-β with antibodies for potential molecular imaging of Alzheimer's disease. (2023) (1)
- Small angle X-ray scattering analysis of Cu- induced oligomers of the Alzheimer’s amyloid b peptide (2015) (1)
- Amyloid- (cid:2) Peptide A (cid:2) 3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons * (2016) (1)
- Quantitative proteomics of detergent insoluble tangles derived from Alzheimer’s disease brains (2021) (1)
- AN EXPLORATORY MOLECULAR IMAGING STUDY TARGETING Aβ WITH A NOVEL 8-OH QUINOLINE IN ALZHEIMER’S DISEASE (THE PBT2-204 IMAGINE STUDY) (2016) (1)
- Erratum to: Cu2+ Coordination of Covalently Cross-linked β-Amyloid Dimers (2014) (1)
- P1-125: Non–β-amyloid, nonoligomeric derivatives of APP are synaptotoxic (2008) (0)
- Mixed Ligand Cu(II) Complexes of a Model Therapeutic with Alzheimer's Amyloid-beta Peptide and Monoamine Neurotransmitters (2014) (0)
- Mapping Novel Copper-Regulated Signalling Pathways Using Antibody Arrays and in Silico Protein Network Analysis (2008) (0)
- Targeting Aβ oligomer formation in Alzheimer’s disease: Challenges and alternatives to oligomer-specific therapeutic avenues (2015) (0)
- Modulation of Alzheimer's disease amyloid beta peptide turnover by metal ligands (2007) (0)
- P1-483: Abeta degradation by matrix metalloproteinase 2 is prevented by factors that induce Abeta amyloid formation (2008) (0)
- Detectable levels of white matter PHF-tau in Alzheimer's disease (2013) (0)
- Role of the amyloid precursor protein and copper in Alzheimer's disease (2013) (0)
- ENGINEERED ANTIBODIES TO TREAT OR PREVENT ALZHEIMER'S DISEASE (2018) (0)
- P3-187 Mutagenesis-toxicity studies of the amyloid beta peptide of Alzheimer's disease (2004) (0)
- NMR SOLUTION STRUCTURE OF THE NEUROTOXIN B-IV, 20 STRUCTURES (1997) (0)
- Blood Borne Aβ Dimer Correlates With Clinical Markers of Alzheimer's Disease (2009) (0)
- DNA platination via S-bound Pt-methionine intermediates (1995) (0)
- Response to Ji et al.: why prion diseases are precluded by non-mammals (2007) (0)
- THE ROLE OF THE APP COPPER BINDING DOMAIN IN REGULATING APP METABOLISM AND STRUCTURE (2011) (0)
- Cisplatin Binding Sites on Human Albumin STRUCTURE: PROTEIN CHEMISTRY AND (2014) (0)
- X-ray Absorption Studies of Metal Binding to the Amyloid β-peptide (2005) (0)
- P2-292: Second generation MPAC PBT2 inhibits tau phosphorylation and promotes Aβ degradation (2008) (0)
- Extracellular vesicular lipids as biomarkers for the diagnosis of Alzheimer’s disease (2021) (0)
- Structure of anti-amyloid-beta Fab WO2 (Form A, P212121) (2008) (0)
- A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort (2017) (0)
- Pathways of DNA platination reactions: Detection of aqua-chloro intermediates (1995) (0)
- Correction to: The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease (2021) (0)
- Palladium analogues of platinum anticancer drugs : Cispalladin and carbopalladin (1993) (0)
- Cu2+ Coordination of Covalently Cross-linked β-Amyloid Dimers (2013) (0)
- Crystal structure of Fab wo2 bound to the n terminal domain of amyloid beta peptide (1-16) (2008) (0)
- Copper and zinc bis(thiosemicarbazonato) complexes for the treatment of Alzheimer's disease (2007) (0)
- Therapeutic benefits of copper-bis (thiosemicarbazonato) complexes in neurodegenerative disorders (2011) (0)
- P3-357 Abeta redox chemistry and neurotoxicity (2006) (0)
- Amyloid-beta remains a membrane peptide after cleavage. implications for secretion and kinetics of abeta turnover in human brain (2015) (0)
- Identification and characterization of disease associated epitopes of mammalian prion proteins (2006) (0)
- Acknowledgment to reviewers 2017 (2017) (0)
- TDP-43 aggregation during chronic oxidative stress is mediated by c-Jun N-terminal kinase and can be inhibited by a potentially therapeutic metallo-complex (2011) (0)
- X-ray Absorption Studies on Structural Consequences of Metal Binding to the Amyloid β-peptide (2004) (0)
- P2.097 A reactive nitrogen species scavenger is neuroprotective in multiple Parkinson's disease animal models (2009) (0)
- O3-05-04: The 8-hydroxyquinoline analog PBT2 rapidly restores cognition and reduces soluble Abeta in Alzheimer transgenic mice (2008) (0)
- The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease (2017) (0)
- The antioligomer effects of the metal-protein attenuating compound clioquinol (2013) (0)
- A mechanism for neurodegenerative disease in the enteric nervous system (2016) (0)
- P1.050 Novel neuroprotective agents for the treatment of Parkinson's disease (2009) (0)
- O3-05-06 EPIGENETIC REGULATION OF TAU GENE EXPRESSION (2019) (0)
- Loss-of-function and gain-of-function studies refute the hypothesis that tau protein is causally involved in the pathogenesis of Huntington's disease. (2022) (0)
- Development of novel SPECT radiotracers for Alzheimer's disease (2012) (0)
- Metal‐based Neurodegeneration: From Molecular Mechanisms to Therapeutic Strategies. By Robert R. Crichton and Roberta J. Ward. (2006) (0)
- Is Covalent Crosslinked A[lower case beta] Responsible for the Neurotoxicity in Alzheimer's Disease? (2007) (0)
- Methode d'identification d'inhibiteurs de la maladie d'alzheimer (2001) (0)
- X-ray absorption spectroscopy study of copper binding to β-amyloid peptide (2007) (0)
- O3-01-08: APP processing in exosomes (2008) (0)
- The structure and function of the amyloid precursor protein N-terminal region (2000) (0)
- Microwave Synthesis of Prion Protein Fragments up to 111 Amino Acids in Length Generates Biologically Active Peptides (2011) (0)
- STRUCTURE OF A NEUROPEPTIDE Y Y2 AGONIST (2000) (0)
- RECENT FINDINGS OF NOVEL BLOOD COMPONENTS’ AMYLOID-BETA MEASURES (2019) (0)
- Preparation of metal complexes for therapeutic uses (2008) (0)
- MODULATING COPPER BIO-AVAILABILITY TO TREAT NEURODEGENERATIVE DISEASES (2009) (0)
- Amyloid-Beta ‘ Oligomers ’ May Be Link to Alzheimer ’ s Dementia (2016) (0)
- P4-283: Dopamine modulates the formation of soluble SDS-stable α-synuclein oligomers via methionine oxidation (2008) (0)
- ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism (2022) (0)
- Copper Coordination by β-Amyloid and the Neuropathology of Alzheimer’s Disease (2007) (0)
- Copper Coordination by β-Amyloid and the Neuropathology of Alzheimer’s Disease (2007) (0)
- The function and composition of brain tissue derived exosomes in human Alzheimer’s disease (2020) (0)
- P2-021: Profiling beta-amyloid in the Alzheimer's disease brain (2012) (0)
- Author Correction: Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer’s disease (2022) (0)
- Crystallization and preliminary X-ray diffraction analysis of the Fab fragment of WO2, an antibody specific for the A[beta] peptides associated with Alzheimer's disease (2008) (0)
- Aβ dimer in the blood correlates with clinical markers of Alzheimer's disease (2010) (0)
- Aβ-INDUCED CALCIUM FLUX IS DEPENDENT ON GLUTAMATE AND COPPER (2014) (0)
- STRUCTURAL STUDIES OF D-PRO MELITTIN, NMR, 20 STRUCTURES (1999) (0)
- 49 Aβ oligomers as diagnostic and therapeutic targets for Alzheimer's disease (2012) (0)
- Crystal structure of anti-amyloid beta FAB WO2 (P21, FormB) (2008) (0)
- Profiling beta-amyloid in the Alzheimer's disease brain (2012) (0)
- O4-08-01 INTRANASAL INSULIN- AND BIOMARKER- ASSOCIATED IMPROVEMENT IN MEMORYAND FUNCTIONAL STATUS IN MILD COGNITIVE IMPAIRMENTAND ALZHEIMER’S DISEASE: RESULTS OFA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT TRIAL (2010) (0)
- Protocol of a Phase II Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of S-Adenosyl Methionine in Participants with Mild Cognitive Impairment or Dementia Due to Alzheimer’s Disease (2023) (0)
- Distribution of isomerized and racemized amyloid β isoforms in sporadic Alzheimer’s disease using ion‐mobility mass spectrometry (2020) (0)
- Pbt2 for Pre-dementia Alzheimer's Disease: Animal and Clinical Evidence (2009) (0)
- GEOGRAPHICAL OF ALZHEIMER’S AGENTS IN THE STATES (2003) (0)
- Alzheimer’s disease β-amyloid protein precursor is a ferroxidase that promotes iron export (2009) (0)
- Inhibition of α-synuclein Aggregation Leads to Therapeutic Benefits in Multiple Animal Models of Parkinson'S Disease. (2010) (0)
- P2-314: Neuroprotective metallo-complexes activate EGFR and inhibit amyloid-beta peptide accumulation (2008) (0)
- The relationship between beta-amyloid protein precursor and tau in Alzheimer's disease-related iron disruption (2011) (0)
- Erratum to: Cu2+ Coordination of Covalently Cross-linked β-Amyloid Dimers (2014) (0)
- Neurological Dysfunction in Early Maturity of a Model for Niemann–Pick C1 Carrier Status (2016) (0)
- Investigating Alzheimer's disease in the blood cellular fraction (2011) (0)
- Factors regulating the interactions between amyloid-beta and membrane lipids (2002) (0)
- NMR Solution structure of NEF1-25, 20 structures (1998) (0)
- A novel effect of bismuth ions: selective inhibition of the biological activity of glycine-extended gastrin (2021) (0)
- Acknowledgement of Reviewers 2014 (2015) (0)
- SOD1 loss accelerates Aß oligomerization and memory impairment in Tg2576 mice (2012) (0)
- P3-446 Significant reduction in 6-hydroxy-dopamine nigral lesion size by administration of clioquinol (2006) (0)
- Investigations of the chemistry of platinum(II) amine complexes (1993) (0)
- Understanding how the Alzheimer's amyloid presursor protein binds copper ions (2005) (0)
- Metal chaperones: An integrated approach to the treatment of Alzheimer's disease (2012) (0)
- Modulation of alpha-synuclein aggregation (2005) (0)
- Correction to: The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kevin Jeffery Barnham?
Kevin Jeffery Barnham is affiliated with the following schools:
